Date: 2011-02-02
Type of information: Fundraising
Company: Scil Proteins (Germany)
Investors: BioNet Holding
Amount: €24 million
Funding type: financing round
Planned used: The funds are intended to finance the development of two products derived from the Company’s Affilin® platform into clinical Phase I over the next three years. Scil Proteins’ Affilin® therapeutics are so called scaffold proteins derived from the human protein Ubiquitin. Affilin® molecules are high affinity binders with excellent target specificity. The Affilin® platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months. Scil Proteins intends to advance into clinical development two Affilin® therapeutic candidates targeting cancer indications.
Others:
Therapeutic area: Cancer - Oncology
